Ryan Rowland, MD
Orthopaedic Surgery · Midland, TXNPI 1740542034
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Arthrex at 30.7% of the total. Reporting peaked in 2022 at $4,153 and has fallen 92.0% since, to $331 in 2025.
Across 147 payments — averaging $93.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$4K
- Stryker$4K
- Rattan And Associates$2K
- Zimmer Biomet$2K
- Johnson & Johnson$839
- Heraeus Medical, LLC.$218
- plus $741 from 15 others
What the payments were for
- Travel & lodging$6,60048%
- Food & beverage$4,58333%
- Education$2,55019%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 30 | $4,218 |
| Stryker | 52 | $3,965 |
| Rattan And Associates | 8 | $2,161 |
| Zimmer Biomet | 16 | $1,592 |
| Johnson & Johnson | 6 | $839 |
| Heraeus Medical, LLC. | 4 | $218 |
| Smith+Nephew | 2 | $186 |
| Amgen | 7 | $151 |
| Bioventus LLC | 3 | $96 |
| Pacira Therapeutics, Inc. | 5 | $83 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Vericel Corporation | 2 | $31 |
| Orthofix Medical, Inc. | 2 | $26 |
| Pylant Medical | 1 | $24 |
| FX Shoulder Solutions, Inc | 1 | $23 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,734 in reported general payments places this provider in the 70th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 294 | $5,244 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 356 | $3,250 |
| Gabapentin | 238 | $2,076 |
| Ondansetron OdtOndansetron | 181 | $1,484 |
| Methocarbamol | 28 | $357 |
| Cephalexin | 111 | $168 |
| Diclofenac Sodium | 12 | $143 |
| Meloxicam | 54 | $97 |
| Tramadol Hcl | 28 | $87 |
| Amoxicillin | 14 | $19 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Midland
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- Robert GrahamAustin$6.3M
- Richard JonesDallas$6.3M
- Stefan KreuzerHouston$6.2M
- Michael WirthSan Antonio$4.5M
- Stephen IncavoHouston$4.3M
- Thomas EdwardsHouston$4.1M
- James BrodskyDallas$2.5M
- Robert SchmidtFort Worth$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.